Medical Research News
In the News: Stay Informed about Astera Cancer Care and Radiation Treatment
Read what’s in the news about Astera Cancer Care and new and developing topics covering radiation treatment for cancer and related subjects.
Paper publication in Lancet Oncology:
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00278-9/fulltext
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
https://pubmed.ncbi.nlm.nih.gov/35839786/
Abstract presentation from AMSOC: Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from cohort 17 of the COSMIC-021 study
https://jitc.bmj.com/content/10/Suppl_2/A597
Recent abstract presentation from ESMO Congress – 481P – A phase I first-inhuman study of XL092 in patients with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 along and in combination with atezeolizumab.
Recent abstract presentation from ASCO Annual Meeting:
[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5002
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9005
Evolution of biomarker testing in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC) in U.S. community practices.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e18778
Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS3635
Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7062
Recent abstract presentation from ASCO GU: A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.095
Recent abstract presentation from ASCO Quality Care: Evaluating the effect of a scalable cancer-navigation program on total cost of care.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.28_suppl.004
Recent abstract presentation from ASTRO: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
https://www.redjournal.org/article/S0360-3016(21)03344-7/fulltext
